about
Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymomaStromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signallingEphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasionMembrane proteins: the key players of a cancer cell.The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology.Vascular endothelial growth factor signaling in acute myeloid leukemia.Signaling and molecular basis of bone marrow niche angiogenesis in leukemia.Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia.EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types.Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.Identification of new possible targets for leukemia treatment by kinase activity profiling.Acute myeloid leukemia in the vascular niche.The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.VEGFC Antibody Therapy Drives Differentiation of AMLRise of the specialized onco-ribosomesThe ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells
P50
Q35583984-62B39840-A111-4B79-A523-F43D039EF15BQ35653943-D6D8ADAB-CE40-4120-8160-2C84A9C11271Q36179161-4E8E1433-8352-4627-A826-49CBF6D52DF2Q37898014-CC4EA71F-C0B1-4794-9CFF-F76398A8EB5EQ37977295-1DFAFF0E-54F2-4E1E-A503-9F7154192EE4Q38029546-D844ECC0-C31D-4D0F-A9D6-DDBCD68EB79AQ38689750-67C09E5F-2B7B-4C48-8C43-5CE0E0F63F07Q38730013-8B4FF022-7C61-4D92-96B8-C61FA5FEC06DQ38871097-3A99E163-1B38-423A-B2C0-FEF1A4974B5DQ38878649-408876AE-CDAA-47B3-9E7A-C101E49A8053Q38969204-A40BA1B2-9C6D-4885-9D52-0271F23F8B02Q38986278-E28DBF36-0E03-480E-85ED-FDBD16F68F55Q39062437-BAF2B8C4-A47D-4D84-8ED9-934AB5F5A45AQ39623499-E1833FF7-42EA-4EB2-B115-DBADED59F808Q40950337-D9671101-0F45-492E-B923-3FEA2412194FQ48027760-4EC54B1F-4630-4F0D-B883-DE0394DBFCD4Q57461983-B9BD9BF6-C18A-4736-8A8B-3AC377E75503Q59133193-FF267D43-8B9D-4DF0-BBAA-E2D0807BF311Q65000502-39B1DBB5-65D0-492A-A395-1AC35D873157Q92666806-9A7B2FB4-2FC2-44F2-96B5-61C56BD95B57
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kim Kampen
@ast
Kim Kampen
@en
Kim Kampen
@es
Kim Kampen
@nl
Kim Kampen
@sl
type
label
Kim Kampen
@ast
Kim Kampen
@en
Kim Kampen
@es
Kim Kampen
@nl
Kim Kampen
@sl
prefLabel
Kim Kampen
@ast
Kim Kampen
@en
Kim Kampen
@es
Kim Kampen
@nl
Kim Kampen
@sl
P106
P31
P496
0000-0001-5065-1272